查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
分子標靶診斷市場:產品與服務,樣本類型,測試類型,技術,應用,最終用戶,地區,機會,預測2017-2031 年
市場調查報告書
商品編碼
1422079

分子標靶診斷市場:產品與服務,樣本類型,測試類型,技術,應用,最終用戶,地區,機會,預測2017-2031 年

Molecular Targeted Diagnostics Market Assessment, By Product & Service, By Sample Type, By Test Type, By Technology, By Application, End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 211 Pages | 商品交期: 3-5個工作天內

價格

全球分子標靶診斷市場規模預計將從 2023 年的 147.5 億美元增至 2031 年的 254.7 億美元，預測期內複合年增長率為 7.07%。 全球分子標靶診斷市場的成長和演變是由伴隨診斷需求不斷增長、技術進步、慢性病擴散、個人化醫療的出現、政府措施和不斷增加的研發投資等因素所推動的。關鍵驅動因素之一是對伴隨診斷的需求不斷增長。伴隨診斷透過識別有助於預測治療效果的特定生物標誌物，在針對個別患者制定治療方案方面發揮重要作用。此外，技術的不斷進步開發出了準確性和精確度不斷提高的先進診斷工具，推動了分子標靶診斷市場的擴張。癌症、心血管疾病和傳染病等慢性疾病的盛行率不斷上升，增加了可靠診斷技術的需求。此外，個人化醫療的出現正在徹底改變醫療保健，強調根據個人的基因組成和特定生物標記量身定制的治療方法。

個性化醫療的出現

個人化醫療的出現是推動分子標靶診斷市場的關鍵因素。這種方法根據患者獨特的基因譜、生物標記和特徵量身定制治療。精準診斷工具，例如分子標靶診斷，對於識別特定的基因改變和生物標記非常重要，而這些基因改變和生物標記對於確定治療策略非常重要。這些診斷工具透過指導針對性治療、預測治療結果和提高患者反應發揮關鍵作用。

加大研發投入

研發資金的增加正在推動診斷技術的技術發展。這些財務投資正在幫助開發更準確、更有效率、更廣泛可用的診斷工具。此外，它還有助於驗證和批准複雜的診斷測試，並且其在各個醫療保健領域的使用正在擴大。資金的增加透過提高診斷準確性和有效性，極大地促進了市場擴張，最終促進了更廣泛的患者護理的改善。

本報告調查了全球分子標靶診斷市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構、影響市場增長的因素分析以及案例研究。 、主要公司簡介等

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章 全球分子標靶診斷市場展望

第 4 章執行摘要

第五章 全球分子標靶診斷市場展望

  • 市場規模/預測
  • 按產品
    • 試劑/試劑盒
    • 機器
    • 服務軟件
  • 依樣品類型
    • 血液、血清、血漿
    • 尿
    • 其他
  • 按測試類型
    • 臨床檢查
    • 概念驗證測試
  • 按技術
    • 等溫核酸擴增技術
    • DNA定序與次世代定序
    • 聚合□鍊式反應
    • 原位雜交
    • DNA微陣列
    • 下一代定序
    • 其他
  • 按用途
    • 傳染病診斷
    • 腫瘤測試
    • 基因測試
    • 驗血
    • 其他
  • 按最終用戶
    • 醫院/診所
    • 診斷實驗室
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 按公司劃分的市場份額

第六章全球分子標靶診斷市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第七章 市場測繪

  • 按產品
  • 依樣品類型
  • 按測試類型
  • 按技術
  • 按用途
  • 按最終用戶
  • 按地區

第八章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第九章市場動態

  • 成長動力
  • 生長抑制因素（問題/障礙）

第 10 章 監理架構/創新

  • 臨床試驗
  • 專利態勢
  • 監管審批
  • 創新/最新技術

第十一章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析
  • 併購/合資（如適用）
  • SWOT分析（5家參與企業）
  • 專利分析（如果適用）

第12章價格分析

第十三章案例研究

第十四章 主要公司展望

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Siemens Healthineers
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • bioMerieux SA
  • QIAGEN Biotechnology Malaysia Sdn Bhd.
  • Danaher Corporation
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

第十五章戰略建議

第十六章關於我們公司/免責聲明

Product Code: MX10944

Global molecular targeted diagnostics Market size was valued at USD 14.75 billion in 2023 which is expected to reach USD 25.47 billion in 2031 with a CAGR of 7.07% for the forecast period between 2024 and 2031. Various factors propel the growth and evolution of the global molecular targeted diagnostics market. Some of the drivers are growing need for companion diagnostics, advancements in technology, a surge in prevalence of chronic diseases, the emergence of personalized medicine, governmental initiatives, and increasing investment in research & development. One of the key drivers of global molecular targeted diagnostics market is the increasing demand for companion diagnostics, which plays a crucial role in tailoring treatments to individual patients by identifying specific biomarkers that assist in predicting treatment responses. Moreover, continuous advancements in technology have led to the development of advanced diagnostic tools that offer enhanced accuracy and precision, fostering the expansion of global molecular targeted diagnostics market. The increasing prevalence of chronic diseases including cancer, cardiovascular diseases, and infectious ailments, has amplified the necessity for reliable diagnostic techniques. Furthermore, the emergence of personalized medicine has revolutionized healthcare by emphasizing treatments tailored to an individual's genetic makeup and specific biomarkers.

Government initiatives supporting precision medicine and healthcare infrastructure expansion, coupled with increasing awareness and patient empowerment regarding the benefits of early diagnosis and targeted treatments, have significantly propelled the adoption of molecular targeted diagnostics. Additionally, significant investments in research and development by pharmaceutical and biotech companies aim to innovate and improve diagnostic tools, fostering growth in global molecular targeted diagnostics market by enhancing accuracy, efficacy, and accessibility.

Advent of Personalized Medicine

The emergence of personalized medicine is a pivotal driver propelling the global molecular targeted diagnostics market. This approach tailors' treatments according to patients' unique genetic profiles, biomarkers, and characteristics. Precision diagnostic tools, like molecular targeted diagnostics, are important for identifying specific genetic alterations and biomarkers critical for determining treatment strategies. These diagnostics tools serve a crucial role by guiding targeted therapies, forecasting treatment outcomes, and enhancing patient responses. As the demand increases for personalized treatments that cater to individual patient needs, the importance of personalized medicine will also increase. Consequently, this surge in significance fuels the broader adoption and utilization of molecular targeted diagnostics across various healthcare settings worldwide. This symbiotic relationship between personalized medicine and molecular targeted diagnostics signifies a transformative shift toward more individualized and effective patient care strategies within the global healthcare landscape.

Increasing in Investments in Research & Development

Technological developments in diagnostic technologies are being driven by increased funding for research and development. These financial investments help develop more accurate, efficient, and widely available diagnostic tools. Additionally, they assist in validating and approving complicated diagnostic tests, broadening their usage across various healthcare domains. This increased funding substantially contributes to the market's expansion by improving diagnostic precision and effectiveness and, ultimately, fostering enhanced patient care on a larger scope. In August 2023, significant financial support was given to researchers at the City of Hope Medical Centre in California to develop a novel targeted chemotherapy. The new targeted chemotherapy showed promising results against all solid tumors in preclinical studies. Targeting proliferating cell nuclear antigen (PCNA), a protein that had been "undruggable," the novel drug candidate AOH1996 appears to eliminate all solid tumors related to PCNA.

Numerous Clinical Benefits of In Situ Hybridization

In situ hybridization (ISH) serves a critical function by allowing visualization and recognition of precise nucleic acid sequences within cells or tissues. This method assists in identifying gene expressions, changes, or disease-causing components, thereby aiding precise disease identification and tailored treatment approaches. As healthcare prioritizes targeted and personalized therapies more, the increased demand for precise molecular diagnostics, notably ISH, fosters the growth of global molecular targeted diagnostics market. This demand facilitates accurate identification and understanding of biomarkers, elevating diagnostic capacities across different diseases globally. In May 2023, Bio-Techne, revealed enhancements in advanced cell diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) range. This extension involves the introduction of an RNAscope multiomic workflow designed for the Standard BioTools Hyperion Imaging System.

Government Initiatives

Governments actively participate in initiatives to enhance molecular targeted diagnostics by creating specialized research hubs. These initiatives are intended to progress research, foster innovation, and encourage the adoption of state-of-the-art diagnostic technologies. By nurturing environments conducive to research and development, these undertakings drive the growth and development of the global molecular targeted diagnostics market. These coordinated government initiatives stimulate technological progress and endorse the validation and assimilation of innovative diagnostic instruments, ultimately augmenting healthcare capabilities and advancing the quality of patient care globally. For instance, in August 2023, Kalyan Singh Super Specialty Cancer Institute (KSSSCI), a distinguished establishment operated by the Government of Uttar Pradesh, collaborated with Karkinos Healthcare and the Indian Institute of Technology Kanpur. This impactful three-way alliance signifies the launch of the 'Centre for Advanced Molecular Diagnostics and Research for Cancer (CAMDRC)', slated to be established in Lucknow.

Growing Demand for Infectious Disease Diagnostics

The rising demand for infectious disease diagnostics acts as a fundamental force propelling the global molecular targeted diagnostics market. This increase in demand arises from the essential need for precise, swift, and specialized diagnostic instruments to detect viruses, bacteria, or parasites accurately. Molecular targeted diagnostics is responsible for promptly identifying and characterizing these infectious agents, allowing for timely treatment choices and strategies to control infections. With persistent challenges posed by infectious diseases in the global healthcare scenario, the amplified necessity for accurate diagnostic tools drives the worldwide expansion and uptake of molecular targeted diagnostics. In April 2023, Thermo Fisher Scientific introduced the inaugural set of 37 CE-IVD-marked real-time PCR assay kits. Primarily designed for diagnosing infectious diseases, these kits are part of the company's plan to unveil a total of 37 such kits within the year. This launch signifies the introduction of Thermo Fisher Scientific's own company-branded test kits, enabling users of its QuantStudio Dx series of instruments to access a diverse range of testing options for the first time.

Outlook of Global Molecular Targeted Diagnostics Market

The future expansion prospects of the global molecular targeted diagnostics market are substantial. Technological advancements, especially in genomics, proteomics, and molecular biology, pave the path for more refined and thorough diagnostic tools. The rising prevalence of chronic illnesses, infectious diseases, and cancer cases on a global scale fuels the need for early detection and personalized therapies, fostering the adoption of molecular targeted diagnostics. Furthermore, the paradigm shifts toward personalized medicine, focusing on customized treatments rooted in individual genetic profiles, intensifies the demand for precise diagnostic methods. Ongoing investments in research and development by pharmaceutical and biotech firms aim to innovate and refine diagnostic precision. Government initiatives backing precision medicine and healthcare infrastructure also play pivotal roles in market growth. As healthcare professionals and patients become increasingly aware of the advantages of early diagnosis, the global molecular targeted diagnostics market is positioned for substantial expansion, leading to improved patient care and treatment outcomes worldwide.

Key Players Landscape and Outlook

Many companies in the global molecular targeted diagnostics market are actively participating in strategic partnerships. These alliances seek to merge knowledge, technologies, and resources to create advanced diagnostic tools. Collaborations facilitate the integration of various expertise and research capabilities, expediting the development of precise and efficient diagnostic solutions. Through leveraging collective strengths, companies navigate complexities, expanding market presence. These collaborations foster synergy, advancing the progress and acceptance of molecular targeted diagnostics. Consequently, they offer improved diagnostic accuracy and effectiveness, ultimately benefiting healthcare systems and global patients. In February 2023, Thermo Fisher Scientific disclosed that its Applied Biosystems TaqPath PCR kits used in diagnosing infectious diseases like multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have obtained licensing approval from the Central Drugs Standard Control Organisation (CDSCO). Thermo Fisher Scientific will collaborate with Mylab Discovery Solutions to produce these kits in India.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Outlook of Global Molecular Targeted Diagnostics Market

4. Executive Summary

5. Global Molecular Targeted Diagnostics Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. Value
    • 5.1.2. Volume
  • 5.2. By Product
    • 5.2.1. Reagents & Kits
    • 5.2.2. Instruments
    • 5.2.3. Services & Software
  • 5.3. By Sample Type
    • 5.3.1. Blood, Serum, and Plasma
    • 5.3.2. Urine
    • 5.3.3. Others
  • 5.4. By Test Type
    • 5.4.1. Lab Tests
    • 5.4.2. PoC Tests
  • 5.5. By Technology
    • 5.5.1. Isothermal Nucleic Acid Amplification Technology
    • 5.5.2. DNA Sequencing & Next-generation Sequencing
    • 5.5.3. Polymerase Chain Reaction
    • 5.5.4. In Situ Hybridization
    • 5.5.5. DNA Microarrays
    • 5.5.6. Next Generation Sequencing
    • 5.5.7. Others
  • 5.6. By Application
    • 5.6.1. Infectious Disease Diagnostics
      • 5.6.1.1. Hepatitis
      • 5.6.1.2. HPV
      • 5.6.1.3. HIV
      • 5.6.1.4. HAI
      • 5.6.1.5. CT/NG
      • 5.6.1.6. Tuberculosis
      • 5.6.1.7. Influenza
      • 5.6.1.8. Others
    • 5.6.2. Oncology Testing
      • 5.6.2.1. Lung Cancer
      • 5.6.2.2. Prostate Cancer
      • 5.6.2.3. Breast Cancer
      • 5.6.2.4. Colorectal Cancer
      • 5.6.2.5. Others
    • 5.6.3. Genetic Testing
    • 5.6.4. Blood Testing
    • 5.6.5. Others
  • 5.7. By End-user
    • 5.7.1. Hospitals & Clinics
    • 5.7.2. Diagnostic Laboratories
    • 5.7.3. Others
  • 5.8. By Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. South America
    • 5.8.4. Asia-Pacific
    • 5.8.5. Middle East and Africa
  • 5.9. By Company Market Share (%), 2022

6. Global Molecular Targeted Diagnostics Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. By Product
      • 6.1.1.1. Reagents & Kits
      • 6.1.1.2. Instruments
      • 6.1.1.3. Services & Software
    • 6.1.2. By Sample Type
      • 6.1.2.1. Blood, Serum, and Plasma
      • 6.1.2.2. Urine
      • 6.1.2.3. Others
    • 6.1.3. By Test Type
      • 6.1.3.1. Lab Tests
      • 6.1.3.2. PoC Tests
    • 6.1.4. By Technology
      • 6.1.4.1. Isothermal Nucleic Acid Amplification Technology
      • 6.1.4.2. DNA Sequencing & Next-generation Sequencing
      • 6.1.4.3. Polymerase Chain Reaction
      • 6.1.4.4. In Situ Hybridization
      • 6.1.4.5. DNA Microarrays
      • 6.1.4.6. Next Generation Sequencing
      • 6.1.4.7. Others
    • 6.1.5. By Application
      • 6.1.5.1. Infectious Disease Diagnostics
      • 6.1.5.1.1. Hepatitis
      • 6.1.5.1.2. HPV
      • 6.1.5.1.3. HIV
      • 6.1.5.1.4. HAI
      • 6.1.5.1.5. CT/NG
      • 6.1.5.1.6. Tuberculosis
      • 6.1.5.1.7. Influenza
      • 6.1.5.1.8. Others
      • 6.1.5.2. Oncology Testing
      • 6.1.5.2.1. Lung Cancer
      • 6.1.5.2.2. Prostate Cancer
      • 6.1.5.2.3. Breast Cancer
      • 6.1.5.2.4. Colorectal Cancer
      • 6.1.5.2.5. Others
      • 6.1.5.3. Genetic Testing
      • 6.1.5.4. Blood Testing
      • 6.1.5.5. Others
    • 6.1.6. By End-user
      • 6.1.6.1. Hospitals & Clinics
      • 6.1.6.2. Diagnostic Laboratories
      • 6.1.6.3. Others
    • 6.1.7. United States*
      • 6.1.7.1. By Product
      • 6.1.7.1.1. Reagents & Kits
      • 6.1.7.1.2. Instruments
      • 6.1.7.1.3. Services & Software
      • 6.1.7.2. By Sample Type
      • 6.1.7.2.1. Blood, Serum, and Plasma
      • 6.1.7.2.2. Urine
      • 6.1.7.2.3. Others
      • 6.1.7.3. By Test Type
      • 6.1.7.3.1. Lab Tests
      • 6.1.7.3.2. PoC Tests
      • 6.1.7.4. By Technology
      • 6.1.7.4.1. Isothermal Nucleic Acid Amplification Technology
      • 6.1.7.4.2. DNA Sequencing & Next-generation Sequencing
      • 6.1.7.4.3. Polymerase Chain Reaction
      • 6.1.7.4.4. In Situ Hybridization
      • 6.1.7.4.5. DNA Microarrays
      • 6.1.7.4.6. Next Generation Sequencing
      • 6.1.7.4.7. Others
      • 6.1.7.5. By Application
      • 6.1.7.5.1. Infectious Disease Diagnostics
      • 6.1.7.5.1.1. Hepatitis
      • 6.1.7.5.1.2. HPV
      • 6.1.7.5.1.3. HIV
      • 6.1.7.5.1.4. HAI
      • 6.1.7.5.1.5. CT/NG
      • 6.1.7.5.1.6. Tuberculosis
      • 6.1.7.5.1.7. Influenza
      • 6.1.7.5.1.8. Others
      • 6.1.7.5.2. Oncology Testing
      • 6.1.7.5.2.1. Lung Cancer
      • 6.1.7.5.2.2. Prostate Cancer
      • 6.1.7.5.2.3. Breast Cancer
      • 6.1.7.5.2.4. Colorectal Cancer
      • 6.1.7.5.2.5. Others
      • 6.1.7.5.3. Genetic Testing
      • 6.1.7.5.4. Others
      • 6.1.7.6. By End-user
      • 6.1.7.6.1.1. Hospital & Clinics
      • 6.1.7.6.1.2. Diagnostic Laboratories
      • 6.1.7.6.1.3. Others
      • 6.1.7.7. Canada
      • 6.1.7.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Product
  • 7.2. By Sample Type
  • 7.3. By Test Type
  • 7.4. By Technology
  • 7.5. By Application
  • 7.6. By End-user
  • 7.7. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Novartis AG
  • 14.3. Abbott Laboratories
  • 14.4. Becton, Dickinson, and Company
  • 14.5. Siemens Healthineers
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Hologic, Inc.
  • 14.8. bioMerieux SA
  • 14.9. QIAGEN Biotechnology Malaysia Sdn Bhd.
  • 14.10. Danaher Corporation
  • 14.11. Illumina, Inc.
  • 14.12. Thermo Fisher Scientific Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 4. Global Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 5. Global Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 6. Global Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 7. Global Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 8. Global Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 9. Global Molecular Targeted Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 12. North America Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 13. North America Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 14. North America Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 15. North America Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 16. North America Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 17. North America Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. North America Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 21. United States Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 22. United States Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 23. United States Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 24. United States Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 25. United States Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 26. United States Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Canada Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Canada Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 30. Canada Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 31. Canada Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 32. Canada Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 33. Canada Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 34. Canada Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 35. Mexico Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 37. Mexico Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 38. Mexico Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 39. Mexico Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 40. Mexico Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 41. Mexico Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 42. Mexico Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 43. Europe Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 45. Europe Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 46. Europe Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 47. Europe Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 48. Europe Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 49. Europe Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 50. Europe Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 51. Europe Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Germany Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 55. Germany Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 56. Germany Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 57. Germany Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 58. Germany Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 59. Germany Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 60. France Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. France Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 63. France Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 64. France Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 65. France Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 66. France Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 67. France Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 68. Italy Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 70. Italy Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 71. Italy Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 72. Italy Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 73. Italy Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 74. Italy Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 75. Italy Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 76. United Kingdom Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 79. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 80. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 81. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 82. United Kingdom Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 83. United Kingdom Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. Russia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 86. Russia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 87. Russia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 88. Russia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 89. Russia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 90. Russia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 91.
  • Figure 92. Russia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 93. Netherlands Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 94. Netherlands Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 95. Netherlands Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 96. Netherlands Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 97. Netherlands Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 98. Netherlands Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 99. Netherlands Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 100. Netherlands Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 101. Spain Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Spain Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Spain Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 104. Spain Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 105. Spain Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 106. Spain Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 107. Spain Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 108. Spain Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 109. Turkey Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. Turkey Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. Turkey Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 112. Turkey Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 113. Turkey Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 114. Turkey Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 115. Turkey Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 116. Turkey Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 117. Poland Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Poland Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Poland Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 120. Poland Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 121. Poland Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 122. Poland Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 123. Poland Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 124. Poland Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 125. South America Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 126. South America Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 127. South America Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 128. South America Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 129. South America Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 130. South America Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 131. South America Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 132. South America Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 133. South America Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 134. Brazil Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 135. Brazil Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 136. Brazil Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 137. Brazil Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 138. Brazil Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 139. Brazil Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 140. Brazil Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 141. Brazil Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 142. Argentina Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 143. Argentina Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 144. Argentina Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 145. Argentina Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 146. Argentina Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 147. Argentina Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 148. Argentina Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 149. Argentina Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 150. Asia-Pacific Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. Asia-Pacific Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 153. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 154. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 155. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 156. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 157. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 158. Asia-Pacific Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 159. India Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 160. India Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 161. India Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 162. India Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 163. India Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 164. India Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 165. India Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 166. India Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 167. China Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. China Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. China Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 170. China Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 171. China Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 172. China Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 173. China Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 174. China Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 175. Japan Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Japan Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Japan Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 178. Japan Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 179. Japan Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 180. Japan Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 181. Japan Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 182. Japan Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 183. Australia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 184. Australia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 185. Australia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 186. Australia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 187. Australia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 188. Australia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 189. Australia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 190. Australia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 191. Vietnam Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 192. Vietnam Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 193. Vietnam Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 194. Vietnam Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 195. Vietnam Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 196. Vietnam Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 197. Vietnam Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 198. Vietnam Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 199. South Korea Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 200. South Korea Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 201. South Korea Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 202. South Korea Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 203. South Korea Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 204. South Korea Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 205. South Korea Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 206. South Korea Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 207. Indonesia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 208. Indonesia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 209. Indonesia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 210. Indonesia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 211. Indonesia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 212. Indonesia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 213. Indonesia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 214. Indonesia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 215. Philippines Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 216. Philippines Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 217. Philippines Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 218. Philippines Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 219. Philippines Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 220. Philippines Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 221. Philippines Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 222. Philippines Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 223. Middle East & Africa Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 224. Middle East & Africa Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 225. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 226. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 227. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 228. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 229. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 230. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 231. Middle East & Africa Molecular Targeted Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 232. Saudi Arabia Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 233. Saudi Arabia Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 234. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 235. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 236. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 237. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 238. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 239. Saudi Arabia Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 240. UAE Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. UAE Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 242. UAE Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 243. UAE Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 244. UAE Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 245. UAE Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 246. UAE Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 247. UAE Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 248. South Africa Molecular Targeted Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 249. South Africa Molecular Targeted Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 250. South Africa Molecular Targeted Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 251. South Africa Molecular Targeted Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 252. South Africa Molecular Targeted Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 253. South Africa Molecular Targeted Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 254. South Africa Molecular Targeted Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 255. South Africa Molecular Targeted Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 256. By Product and Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023